PMID- 28737225
OWN - NLM
STAT- MEDLINE
DCOM- 20180625
LR  - 20180625
IS  - 1531-8257 (Electronic)
IS  - 0885-3185 (Linking)
VI  - 32
IP  - 11
DP  - 2017 Nov
TI  - Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's
      disease.
PG  - 1566-1573
LID - 10.1002/mds.27101 [doi]
AB  - BACKGROUND: Dopamine replacement therapy in PD has been associated with both
      behavioral addictions and dopamine addiction. OBJECTIVES: To investigate
      potential association between l-dopa induced neuropsychiatric fluctuations and
      addictions in PD. METHODS: A cohort of 102 patients with PD suffering from motor 
      complications of l-dopa treatment was prospectively analyzed. We evaluated
      dopamine addiction, behavioral addictions, and neuropsychiatric fluctuations
      using the Ardouin scale of behavior in PD. RESULTS: Patients with (n = 51) or
      without (n = 51) neuropsychiatric fluctuations did not differ in age, disease
      duration, medication, or UPDRS III motor score during on and off drug condition. 
      Patients with neuropsychiatric fluctuations had a higher H & Y stage in off-drug 
      condition. A multivariate model showed that dopamine addiction (odds ratio: 8.9; 
      P = 0.02) and behavioral addictions (odds ratio: 3.76; P = 0.033) were more
      frequent in the presence of neuropsychiatric fluctuations. Behavioral addictions 
      and dopamine addiction were more frequent in the presence than in the absence of 
      on-drug euphoria (46% vs. 13.9%; P < 0.001 and 27% vs 6.2 %; P = 0.003), while
      conversely, no association emerged between dopamine or behavioral addictions and 
      presence of off-drug dysphoria. Patients with neuropsychiatric fluctuations had a
      poorer quality of life and a more frequent history of anxiety disorder.
      CONCLUSIONS: The psychostimulant effects of dopamine treatment during on-drug
      euphoria, rather than avoidance of off-drug dysphoria, appear to drive both
      behavioral addictions and abuse of medication. (c) 2017 International Parkinson
      and Movement Disorder Society.
CI  - (c) 2017 International Parkinson and Movement Disorder Society.
FAU - Delpont, Benoit
AU  - Delpont B
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
FAU - Lhommee, Eugenie
AU  - Lhommee E
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
FAU - Klinger, Helene
AU  - Klinger H
AD  - Service de Neurologie C, Universite Lyon I, Hospices Civils de Lyon, Hopital
      Neurologique Pierre Wertheimer, Lyon, France.
AD  - CNRS, UMR 5229, Centre de Neurosciences Cognitives, Lyon, France.
FAU - Schmitt, Emmanuelle
AU  - Schmitt E
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
FAU - Bichon, Amelie
AU  - Bichon A
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
FAU - Fraix, Valerie
AU  - Fraix V
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
FAU - Castrioto, Anna
AU  - Castrioto A
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
FAU - Quesada, Jean-Louis
AU  - Quesada JL
AD  - Unite Scientifique de la DRCI et Centre d'Investigation Clinique, CHU de
      Grenoble, Grenoble, France.
FAU - Pelissier, Pierre
AU  - Pelissier P
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
FAU - Kistner, Andrea
AU  - Kistner A
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
FAU - Carnicella, Sebastien
AU  - Carnicella S
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
FAU - Luscher, Christian
AU  - Luscher C
AD  - Department of Basic Neurosciences, Medical Faculty, University of Geneva, Geneva,
      Switzerland; Clinic of Neurology, Department of Clinical Neurosciences, Geneva
      University Hospital, Geneva, Switzerland.
FAU - Broussolle, Emmanuel
AU  - Broussolle E
AD  - Service de Neurologie C, Universite Lyon I, Hospices Civils de Lyon, Hopital
      Neurologique Pierre Wertheimer, Lyon, France.
AD  - CNRS, UMR 5229, Centre de Neurosciences Cognitives, Lyon, France.
FAU - Pollak, Pierre
AU  - Pollak P
AD  - Department of Basic Neurosciences, Medical Faculty, University of Geneva, Geneva,
      Switzerland; Clinic of Neurology, Department of Clinical Neurosciences, Geneva
      University Hospital, Geneva, Switzerland.
FAU - Thobois, Stephane
AU  - Thobois S
AD  - Service de Neurologie C, Universite Lyon I, Hospices Civils de Lyon, Hopital
      Neurologique Pierre Wertheimer, Lyon, France.
AD  - CNRS, UMR 5229, Centre de Neurosciences Cognitives, Lyon, France.
FAU - Krack, Paul
AU  - Krack P
AD  - Movement Disorders Unit, Neurology Department, CHU Grenoble Alpes and Universite 
      Grenoble Alpes, Grenoble, France.
AD  - Grenoble Institut des Neurosciences, Inserm, U1216, Grenoble, France.
AD  - Department of Basic Neurosciences, Medical Faculty, University of Geneva, Geneva,
      Switzerland; Clinic of Neurology, Department of Clinical Neurosciences, Geneva
      University Hospital, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20170724
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Dopamine Agents)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Aged
MH  - Behavior, Addictive/chemically induced/*physiopathology
MH  - Central Nervous System Stimulants/*adverse effects
MH  - Depressive Disorder/*physiopathology
MH  - Dopamine Agents/*adverse effects
MH  - Dyskinesia, Drug-Induced/physiopathology
MH  - Euphoria/*drug effects
MH  - Female
MH  - Humans
MH  - Levodopa/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/drug therapy/*physiopathology
MH  - Prospective Studies
MH  - Substance-Related Disorders/*physiopathology
OTO - NOTNLM
OT  - Parkinson's disease
OT  - addictions
OT  - dopamine dysregulation syndrome
OT  - impulsive control disorders
OT  - nonmotor fluctuations
EDAT- 2017/07/25 06:00
MHDA- 2018/06/26 06:00
CRDT- 2017/07/25 06:00
PHST- 2016/07/05 00:00 [received]
PHST- 2017/05/23 00:00 [revised]
PHST- 2017/06/04 00:00 [accepted]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2018/06/26 06:00 [medline]
PHST- 2017/07/25 06:00 [entrez]
AID - 10.1002/mds.27101 [doi]
PST - ppublish
SO  - Mov Disord. 2017 Nov;32(11):1566-1573. doi: 10.1002/mds.27101. Epub 2017 Jul 24.